Medicine News and Research

RSS

Researchers receive NIH award to investigate regenerative potential of retinal cells

Zhang and co-principal investigators Sheng Ding, PhD, from The Scripps Research Institute, and Thomas Reh, PhD from the University of Washington, received the highest possible scores for their proposal to investigate the regenerative potential of retinal cells. Their long-term goal is to restore visual function lost through diseases such as macular degeneration and retinitis pigmentosa.

30 Sep 2010

Mammogram for women over 40: Debate continues

A report this Wednesday showed that routine screenings for breast cancer called mammograms cut the breast cancer death rate by 26 percent for women in their 40s. The results have been received in a mixed way by experts.

30 Sep 2010

ACT updates myoblast program for heart failure treatment

Advanced Cell Technology, a leader in the field of regenerative medicine, provided an update today on the status of its myoblast program. The program has successfully and safely completed Phase I human clinical trials in more than forty patients in over four independent studies.

30 Sep 2010

Study: Racial disparities in end-of-life care

A new study in the Archives of Internal Medicine finds that black patients and white patients may not receive the same quality in end-of-life care.

30 Sep 2010

Duke receives approval to initiate NPC-1C Phase I trial for advanced pancreatic and colorectal cancer

Neogenix Oncology, Inc. announced today that researchers at Duke University Medical Center have received approval to move forward with a Phase I trial of the company's lead therapeutic antibody, NPC-1C, in patients with advanced stage pancreatic or colorectal cancer. Duke joins Johns Hopkins Hospital which is already conducting the Phase I trial of NPC-1C. In addition to Johns Hopkins, North Shore - LIJ has also enrolled patients on this multi-center study.

30 Sep 2010

Stress-factors leading to mental problems and burnout in IT-industries

According to health insurances, employees in IT-industries are very fit. By using an online-survey, Technische Universität Dortmund monitored this statement in cooperation with some freelancer-networks. Results indicate that this is due to the phenomenon "presentism"- meaning IT-employees do not appear in health insurance statistics as they continue to work even when they are ill. Actually, the sample reported on distinct health problems- predominantly musculoskeletal problems and mental afflictions.

30 Sep 2010

New immunotherapy regimen improves survival rate in children with neuroblastoma: Research

Administering a new form of immunotherapy to children with neuroblastoma, a nervous system cancer, increased the percentage of those who were alive and free of disease progression after two years, according to researchers at the University of California, San Diego School of Medicine and fellow institutions.

30 Sep 2010

Researchers discover genes that influence human height

An international team of researchers, including a number from the University of North Carolina at Chapel Hill schools of medicine and public health, have discovered hundreds of genes that influence human height.

30 Sep 2010

Alnylam Pharmaceuticals publishes ALN-RSV01 Phase IIa study results

Alnylam Pharmaceuticals, Inc. a leading RNAi therapeutics company announced today that it has published results in the American Journal of Respiratory and Critical Care Medicine from its double-blind, placebo-controlled, randomized Phase IIa study of ALN-RSV01 in lung transplant patients naturally infected with respiratory syncytial virus (RSV).

30 Sep 2010

Michigan University researchers receive funds to study breast cancer risk factors

A team of researchers led by a Michigan State University scientist has been awarded $14 million to identify risk factors for breast cancer in young women, focusing on growth, diet, physical activity and body size during a woman's lifetime.

30 Sep 2010

Breakthrough neuroblastoma treatment

According to a new study the addition of an experimental immunotherapy drug to the standard regimen of care extended the lives and decreased the risk of a disease recurrence in children with high-risk neuroblastoma. This tumor most frequently originates in one of the adrenal glands, but can also develop in nerve tissues in the neck, chest, abdomen, or pelvis. It forms 12 percent of cancer-related deaths in children under the age of 15 and half of patients with this type of malignancy have the high-risk form.

29 Sep 2010

Circadian partners with Cincinnati Children's Hospital to develop blood test diagnostic for LAM, a serious lung disease

Circadian Technologies (ASX.CIR) has announced today that it has partnered with Cincinnati Children’s Hospital Medical Centre (CCHMC) to develop and market a blood test to diagnose LAM, a serious lung disease that strikes women, usually in their child bearing years.

29 Sep 2010

Unique genetic markers point to patient response to SCV-07 treatment

SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that researchers have identified two unique gene clusters that differentiated subjects who responded to treatment in the Company’s phase 2a proof of concept study of SCV-07 for the prevention of severe oral mucositis (OM; WHO grades 3-4) in patients with advanced head and neck cancer.

29 Sep 2010

Keryx commences Zerenex Phase 3 study for hyperphosphatemia in patients with ESRD on dialysis

Keryx Biopharmaceuticals, Inc. announced today the initiation of the long-term Phase 3 study of Zerenex™ (ferric citrate), the Company's iron-based phosphate binder for the treatment of elevated serum phosphorous levels, or hyperphosphatemia, in patients with end-stage renal disease (ESRD) on dialysis.

29 Sep 2010

NIAID study utilizes Biojector B2000 system to explore syringe, needle benefits

Bioject Medical Technologies Inc., a leading developer of needle-free injection therapy systems, today announced that its unique Needle-Free Injection Therapy (NFIT) system, the Biojector 2000, is being utilized in a study sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) which is part of the U.S. National Institutes of Health (NIH).

29 Sep 2010

IN.PACT drug-eluting balloons show promising results for superficial femoral artery disease treatment

Advancing research on drug-eluting balloons for the treatment of coronary and peripheral artery disease, Medtronic, Inc., today announced the latest results from the IN.PACT drug-eluting balloon (DEB) clinical program presented last week at the Transcatheter Cardiovascular Therapeutics (TCT) 2010 conference.

29 Sep 2010

AccessClosure enters agreement with Benrikal Services for Bengal Radial Compression Band distribution

AccessClosure, Inc., the market leader in extravascular closure devices, announced today an exclusive agreement with Benrikal Services to distribute the Bengal Radial Compression Band in the United States.

29 Sep 2010

New program offers options for fertility preservation in children with cancer

It is estimated that 1 in 500 children will be diagnosed with a form of childhood cancer. Fortunately, with the use of aggressive treatment modalities, more than 75% of these children will be cured. Therefore, many of these children and parents are looking beyond the cancer at important quality of life issues and guiding their treatments to assure "normal" post-cancer survivorship.

29 Sep 2010

XOMA completes patient enrollment in XOMA 052 Phase 2a trial

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced that patient enrollment was recently completed for the company's Phase 2a trial of XOMA 052 in patients with Type 2 diabetes.

29 Sep 2010

Patients' right to be involved in own medical care

Twelve years ago, then 28-year-old graduate student Brian Zikmund-Fisher was forced into the toughest choice of his life: Die from a blood disorder within a few years or endure a bone marrow transplant that could cure him or kill him in weeks.

29 Sep 2010

Medicine News and Research

Researchers receive NIH award to investigate regenerative potential of retinal cells

Mammogram for women over 40: Debate continues

ACT updates myoblast program for heart failure treatment

Study: Racial disparities in end-of-life care

Duke receives approval to initiate NPC-1C Phase I trial for advanced pancreatic and colorectal cancer

Stress-factors leading to mental problems and burnout in IT-industries

New immunotherapy regimen improves survival rate in children with neuroblastoma: Research

Researchers discover genes that influence human height

Alnylam Pharmaceuticals publishes ALN-RSV01 Phase IIa study results

Michigan University researchers receive funds to study breast cancer risk factors

Breakthrough neuroblastoma treatment

Circadian partners with Cincinnati Children's Hospital to develop blood test diagnostic for LAM, a serious lung disease

Unique genetic markers point to patient response to SCV-07 treatment

Keryx commences Zerenex Phase 3 study for hyperphosphatemia in patients with ESRD on dialysis

NIAID study utilizes Biojector B2000 system to explore syringe, needle benefits

IN.PACT drug-eluting balloons show promising results for superficial femoral artery disease treatment

AccessClosure enters agreement with Benrikal Services for Bengal Radial Compression Band distribution

New program offers options for fertility preservation in children with cancer

XOMA completes patient enrollment in XOMA 052 Phase 2a trial

Patients' right to be involved in own medical care

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News